Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Lunai Bioworks (NASDAQ: LNAI) subsidiary BioSymetrics signed a non-binding LOI with Geneial to convert patient-led rare neurological datasets into trial-ready cohorts and pursue commercial pharma partnerships.

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) subsidiary BioSymetrics signed a non-binding LOI with Geneial to convert patient-led rare neurological datasets into trial-ready cohorts and pursue commercial pharma partnerships. Initial programs will integrate longitudinal registry data to identify patient subgroups and enable cohort activation for translational and clinical development.

Argus Apr 15 session

-4.69% close to close Open Argus

Details

News Market Reaction – LNAI

On Apr 15, the day this news came out, LNAI closed 4.69% below the previous close.

Data tracked by StockTitan Argus for the Apr 15 session.

Key Figures

Rare disease population: 300 million people

Rare disease population

300 million people

Global rare disease patients referenced in LOI announcement

Historical Context

5 past events · Latest: Apr 07

5 events

1. Apr 07

   Defense collaboration win

   24h Move

   +39.8%

   Multi-year, revenue-generating defense collaboration using BioSymetrics AI platform.

2. Mar 26

   CNS acquisition deal

   24h Move

   +22.9%

   $20M strategic acquisition of BBB CNS platform via fixed-price preferred shares.

3. Mar 19

   Chemical defense consortium

   24h Move

   -4.2%

   Launch of Pathfinder Consortium targeting large U.S. countermeasure procurement programs.

4. Feb 19

   Core AI patent

   24h Move

   -1.4%

   Issuance of U.S. patent on data debiasing architecture for AI drug discovery.

5. Feb 13

   Media platform feature

   24h Move

   -10.2%

   CNBC segment highlighting AI platform for CNS and biodefense applications.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

letter of intent (loi), longitudinal clinical data, trial-ready cohorts

3 terms

letter of intent (loi) financial

"BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI)"

A letter of intent (LOI) is a written document that outlines the main terms and intentions of parties planning to work together or make a transaction. It serves as a preliminary agreement, indicating serious interest and helping to clarify expectations before a formal contract is signed. For investors, an LOI signals that negotiations are progressing and provides a foundation for more detailed agreements to follow.

longitudinal clinical data medical

"incorporating longitudinal clinical data to support cohort development"

Data collected from the same patients repeatedly over time to track how a treatment or condition changes, like a diary or a video that shows progress instead of a single snapshot. Investors care because this long-term view reveals whether benefits last, side effects appear, or outcomes shift with real-world use, shaping regulatory decisions, market adoption and forecasts for future sales and risks.

trial-ready cohorts technical

"creation and activation of trial-ready patient cohorts that can support"

Groups of people who have already been identified, screened for eligibility, and often pre-consented to join a specific type of clinical study, so they can be enrolled quickly when a trial opens. For investors, these ready-made participant pools reduce the time, cost, and uncertainty of recruiting subjects—like having a pre‑assembled roster of players—speeding up drug development milestones and lowering the risk that delays will eat into a company’s timeline or budget.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities.

Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies.

SACRAMENTO, Calif., and HOUSTON, April 15, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and patient engagement company, today announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI) with Geneial to pursue a strategic collaboration in rare neurological disorders.

The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships.

Rare diseases affect approximately 300 million people globally, yet drug development remains constrained by limited access to structured, usable patient data. The targeted rare neurological segment represents a multi-billion-dollar and growing market opportunity.

Initial programs are expected to integrate datasets across multiple patient registries, incorporating longitudinal clinical data to support cohort development and translational research across indications.

Under the proposed collaboration, BioSymetrics and Geneial plan to:

• Integrate and standardize patient-led rare disease datasets
• Identify defined patient subgroups for clinical development
• Generate actionable insights to support therapeutic programs
• Enable the activation of trial-ready cohorts for pharma and biotech engagement

This approach is intended to reduce development risk, improve the probability of trial success, and accelerate timelines by addressing a key bottleneck in rare disease drug development: connecting longitudinal patient data and engaged cohorts with translational research and clinical development opportunities.

The companies expect to pursue commercial partnerships enabled by these efforts, supporting potential revenue-generating collaborations and downstream partnering opportunities with pharmaceutical and biotechnology partners.

"Geneial's mission is to accelerate precision medicine by connecting patient communities, researchers, and industry partners," said Adam Hansen, CEO of Geneial. "This collaboration connects our AI-enabled patient engagement and data platform with BioSymetrics' capabilities to translate real-world data into targeted therapies and accelerate development timelines."

"Rare neurological disorders represent a large unmet need, but the underlying data have historically been difficult to use," said Gabe Musso, Chief Scientific Officer of BioSymetrics. "This collaboration is focused on making that data actionable for developmental programs and enabling a more efficient path toward the clinic."

Geneial and BioSymetrics will combine patient engagement infrastructure with data integration and analysis capabilities to support therapeutic development and clinical pathway design.

The initial focus will include select rare neurodevelopmental disorders, with the goal of building scalable programs that can expand over time.

The LOI is non-binding. Specific projects and commercial terms are expected to be defined in future definitive agreements.

About Lunai Bioworks
Lunai Bioworks (NASDAQ: LNAI) is an AI-driven biotechnology company focused on accelerating drug discovery and development across central nervous system (CNS) and other high unmet need areas. Lunai integrates data analytics and experimental biology to improve development efficiency, reduce cost, and increase probability of success. For more visit https://lunaibioworks.com.

About Geneial
Geneial is an AI-powered precision medicine data infrastructure company focused on rare and genetic diseases. Its platform integrates patient engagement, longitudinal data, and semantic interoperability, connecting patients, researchers, and industry partners to accelerate therapeutic development and care navigation. For more visit https://geneial.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected scope, objectives, and potential benefits of the proposed collaboration, the potential development of datasets and patient cohorts, and the possibility of future commercial partnerships. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially.

Factors that could affect outcomes include the parties' ability to enter into definitive agreements, advance proposed projects, generate and validate data, secure partnerships, obtain necessary funding or regulatory support, and realize the anticipated benefits of the collaboration. Lunai undertakes no obligation to update forward-looking statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-and-geneial-sign-loi-to-build-rare-disease-patient-cohorts-for-pharma-partnerships-302743186.html

SOURCE Lunai Bioworks Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lunai Bioworks (LNAI) announce in the April 15, 2026 LOI with Geneial?

They signed a non-binding LOI to collaborate on converting patient-led rare neurological data into trial-ready cohorts. According to Lunai and Geneial, the effort will integrate longitudinal registries, standardize datasets, and identify patient subgroups to support pharma partnerships and translational programs.

How will the Lunai-Geneial collaboration support rare disease drug development for LNAI?

By integrating and standardizing fragmented patient datasets to create actionable cohorts for trials. According to the companies, this approach aims to reduce development risk, improve trial probability of success, and accelerate timelines by connecting longitudinal data with translational research.

Which patient populations are the initial Lunai and Geneial programs focusing on under the LOI?

Initial focus is on select rare neurodevelopmental and rare neurological disorders to build scalable cohorts. According to the companies, the programs will target longitudinal registry data to support cohort development and expand over time to additional indications.

Does the LOI between BioSymetrics (Lunai) and Geneial create binding commercial obligations for LNAI?

No, the LOI is expressly non-binding and does not establish final commercial terms. According to the companies, specific projects, commercial terms, and definitive agreements will be defined in future binding contracts if both parties proceed.

What commercial opportunities could the Lunai-Geneial collaboration enable for shareholders of LNAI?

The collaboration aims to enable revenue-generating pharma and biotech partnerships tied to trial-ready cohorts. According to the companies, integrated datasets and cohort activation could support downstream partnering opportunities and commercial collaborations if definitive agreements are reached.

How will BioSymetrics and Geneial handle patient data to build cohorts for LNAI projects?

They plan to integrate, standardize, and analyze patient-led datasets to identify defined subgroups and actionable insights. According to the companies, this includes combining patient engagement infrastructure with data integration to support translational research and clinical pathway design.